AbCellera Biologics (AbCellera Biologics) Gross Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is AbCellera Biologics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. AbCellera Biologics's Gross Profit for the three months ended in Mar. 2024 was $9.95 Mil. AbCellera Biologics's Revenue for the three months ended in Mar. 2024 was $9.95 Mil. Therefore, AbCellera Biologics's Gross Margin % for the quarter that ended in Mar. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.

The historical rank and industry rank for AbCellera Biologics's Gross Margin % or its related term are showing as below:

During the past 6 years, the highest Gross Margin % of AbCellera Biologics was 88.36%. The lowest was 86.31%. And the median was 87.87%.

ABCL's Gross Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: 60.9
* Ranked among companies with meaningful Gross Margin % only.

AbCellera Biologics had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for AbCellera Biologics was 0.00% per year.

AbCellera Biologics Gross Margin % Historical Data

The historical data trend for AbCellera Biologics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Gross Margin % Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

88.36

87.87

86.31

AbCellera Biologics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of AbCellera Biologics's Gross Margin %

For the Biotechnology subindustry, AbCellera Biologics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbCellera Biologics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's Gross Margin % falls into.

AbCellera Biologics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

AbCellera Biologics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	38	/	38.025
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(38.025 - 0)	/	38.025
	=	N/A %

AbCellera Biologics's Gross Margin for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )	=	Gross Profit (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	10	/	9.954
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(9.954 - 0)	/	9.954
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

AbCellera Biologics (NAS:ABCL) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

AbCellera Biologics had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

AbCellera Biologics Gross Margin % Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AbCellera Biologics (AbCellera Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (NAS:ABCL) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

8QQ:Germany

Address

2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1

Website

https://www.abcellera.com

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Executives

John S. Montalbano	director	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Michael R Hayden	director	C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Veronique Lecault	director, officer: Chief Operating Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Thermopylae Holdings Ltd.	10 percent owner	2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Booth	officer: Chief Financial Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Lo	director	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
John Hamer	director, 10 percent owner	PO BOX 14528, RESEARCH TRIANGLE PARK NC 27709-4528
Ester Falconer	officer: Chief Technology Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Hansen Carl L. G.	director, 10 percent owner, officer: Chief Executive Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Tryn Stimart	officer: Chief Legal Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Peter Thiel	director	9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Dcvc Bio, L.p.	10 percent owner	317 UNIVERSITY AVENUE, SUITE 200, PALO ALTO CA 94301
Dcvc Bio Gp, Llc	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Zachary Bogue	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Matthew Ocko	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301